In the AURA 3 randomized phase III trial [56], osimertinib significantly prolonged median PFS and ORRs than cisplatin plus pemetrexed in T790M positive NSCLC patients who had disease progression after first-line EGFR-TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.